NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SAIPARENT · data 2026-10-30
Sai Parenterals Limited
In plain words
Price: 26.1% below its 52-week high of ₹706.
Delivery: 54.0% of traded shares were kept for delivery over the last 10 sessions, against 55.1% over the last 60.
Latest results: a net profit of ₹8 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | — |
| Net profit (last 12 months) | — |
| Sales growth, 3 years (yearly) | 57.9% |
| Profit growth, 3 years (yearly) | 48.3% |
Latest results in brief (Q4 FY26)
SAIPARENT Q4 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹197.93 crore.
Net profit was ₹13.16 crore.
Operating margin was 13.2%.
EPS was ₹4.02.
SAIPARENT के Q4 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹197.93 करोड़।
शुद्ध मुनाफ़ा: ₹13.16 करोड़।
ऑपरेटिंग मार्जिन: 13.2%।
EPS: ₹4.02।
SAIPARENTના Q4 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹197.93 કરોડ.
ચોખ્ખો નફો: ₹13.16 કરોડ.
ઓપરેટિંગ માર્જિન: 13.2%.
EPS: ₹4.02.
Written from the filed numbers. Not a recommendation.
Smart-money activity
21/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 53.9% over the last 20 sessions vs 47.7% in the 40 before (1.13x); shares delivered per day 1.44x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 2/15: Verdict "None", sustained score 59/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 23 May 26Results Q4 FY26 results: net profit ₹13.2 cr +0.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹179 cr | ₹8 cr | — | 13.2% | 1.79 |
Shareholding trend
| Holder | Sept 2026 |
|---|---|
| Promoters | 51.16% |
| Foreign institutions (FII) | 2.85% |
| Domestic institutions (DII) | 7.84% |
| Mutual funds | 0.30% |
| Retail investors | 9.56% |
| Number of shareholders | 13,645 |
Common questions
What was Sai Parenterals Limited's latest quarterly profit?
Sai Parenterals Limited reported a net profit of ₹8 cr for the quarter ended Jun 2026, on revenue of ₹179 cr.
How much do promoters hold in Sai Parenterals Limited?
Promoters held 51.16% of Sai Parenterals Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Sai Parenterals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.96.
What is the 52-week high and low of Sai Parenterals Limited?
The 52-week high is ₹706 and the 52-week low is ₹400.
Similar companies
Fredun Pharmaceuticals Ltd. (FREDUN) · Dishman Carbogen Amcis Ltd. (DCAL) · Alembic Limited (ALEMBICLTD) · Sakar Healthcare Ltd (SAKAR) · Beta Drugs Ltd. (BETA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SAIPARENT in NSE Scanner →